Kevin Tracey

Study: Bust the burgers, go nuts for reflux

By GREGORY ZELLER // This just in from the Insult to Injury Department: Victims of acid reflux can defeat the dreaded disorder without choking down a lifetime of pharmaceuticals – simply by eliminating every single tasty thing on Earth, everywhere, forever. The slightly-less-dramatic version: A plant-based “Mediterranean-style diet” can provide the same medical benefits as popular pharmaceutical options for treating laryngopharyngeal reflux. So says the Journal of the American Medical Association, which on Thursday published…


ALZ: Genetic variants can run, but they can’t hide

The Feinstein Institute for Medical Research is targeting genetic risk factors behind Alzheimer’s disease, the first of many steps toward new potential treatments. Feinstein Institute assistant professor Yun Freudenberg-Hua has been awarded a five-year, $600,000 grant by the National Institutes of Health’s National Institute on Aging, supporting her mission to better understand the genetic causes of a disease that inflicts an estimated 5.5 million Americans. Ultimately, the doctor and her staff hope to develop new…


Feinstein researchers eye brain-tumor breakthrough

A common medication used to treat parasitic infections could leapfrog to the top of medical science’s brain-cancer arsenal. Pure scientific research funded by federal grants has led to this potential oncological breakthrough by the Feinstein Institute for Medical Research, the research-and-development division of the Northwell Health system. Marc Symons, a professor in the Feinstein Institute’s Karches Center for Oncology Research, is exploring the use of mebendazole – a medication commonly used to treat pinworms –…


Northwell, drug-maker ink bioelectronics partnership

By GREGORY ZELLER // Bioelectronic medicine has taken another forward leap, thanks to the Feinstein Institute for Medical Research’s latest professional alliance. The research-and-development arm of the Northwell Health system announced Thursday that it will apply its cutting-edge bioelectronics and cell-therapy technologies to cardiology and hypertension cases through a new “strategic partnership” with United Therapeutics Corp. Financial terms were not disclosed, but United Therapeutics will “fund Northwell’s efforts in four research-and-development tracks” while ushering new…


Rockefeller researcher nabs Feinstein’s molecular prize

Advanced molecular-genetics studies have earned a Rockefeller University researcher accolades from the Feinstein Institute for Medical Research, and a fat check. While Feinstein Institute scientists are often the ones collecting the research prizes, this time the institute is dishing it out, naming Jeffrey Ravetch – head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University in New York City – the recipient of the fifth-annual Ross Prize in Molecular Medicine….


GE brings good things to bioelectronics research

By GREGORY ZELLER // General Electric is giving the Feinstein Institute for Medical Research a bioelectronic jolt. The Feinstein Institute, R&D mecca of the Northwell Health system, announced a new “strategic alliance” Tuesday with GE Ventures, the multinational conglomerate’s New Jersey-based business-licensing and equity arm. While no financial terms were disclosed, Northwell Health did note an “investment” that will help the Feinstein Institute’s evolving Center for Bioelectronic Medicine “continue its work in discovering, developing and…


Feinsteins donate $25M (again) to Northwell research

By GREGORY ZELLER // The Feinsteins have gone Bed, Bath & Beyond the call of duty, once again. Susan Feinstein and her husband, Leonard, co-founder and co-chairman of the New Jersey-based national housewares chain, announced Friday a fresh $25 million donation to Northwell Health’s Feinstein Institute for Medical Research – the health system’s busy Manhasset R&D hub, renamed in 2005 following the Feinsteins’ first $25 million gift. The new endowment will “further expand its research…


LI Bioscience Hub backs 10 in new funding round

By GREGORY ZELLER // A fresh batch of commercially promising biomedical innovations has been funded by the Long Island Bioscience Hub. The LIBH’s third round of grant awards – bestowed upon 10 distinct applicants hailing from Stony Brook University, Cold Spring Harbor Laboratory and the Feinstein Institute for Medical Research, three of the hub’s four partner institutions – totals $550,000. Stony Brook-based research earned seven of the awards, including the only $100,000 “proof of concept”…


New veeps target Feinstein Institute growth

Hungry for growth, the Feinstein Institute for Medical Research has beefed up its administrative team. Following a year of groundbreaking research and ambitious business ventures, the bioelectronic medicine-friendly institute has named John David Chelico its new vice president of research information technology and Ivar Strand its new vice president of research finance, a position that monitors critical bottom-line practices around Feinstein’s breakthrough R&D. Both Chelico – who will be tasked with developing a “data core”…


Nerves of steel: Sanguistat stimulator steps up

By GREGORY ZELLER // The world’s leading cause of maternal deaths is the target of new clinical trials for a trailblazing bioelectronic medical device. The Neural Tourniquet, an electronic nerve-stimulation technology licensed to Sanguistat Inc. by the Feinstein Institute for Medical Research, is seeing action against postpartum hemorrhage in new clinical trials underway at Feinstein, the research arm of the Northwell Health system. Sanguistat, a 2016 clinical-stage medical device spinoff founded by Feinstein Vice President…


Centricity event highlights Feinstein heart, tech

By GREGORY ZELLER // The Feinstein Institute flexed its investigative muscle Nov. 10, highlighting the awesome breadth of its clinical research programs in a day-long symposium at its Manhasset headquarters. Covering everything from cutting-edge neurosurgical techniques to shifting paradigms in thromboembolic-disease research to new mental illness-related technologies, Centricity Series Symposia: Clinical Research 2016 was designed specifically to show how the Feinstein Institute for Medical Research, the R&D arm of the Northwell Health system, is improving…


Debrief: Scientifically, Kevin Tracey is all business

Fresh off keynoting an international symposium at the New York Academy of Sciences, bioelectronic medicine pioneer Kevin Tracey is (as usual) busily overseeing operations at the groundbreaking Feinstein Institute for Medical Research. That includes bioelectronics R&D, though Tracey is adamant that science – not sales – is Feinstein’s focus (example: he claims no involvement with a spinoff company based on his nerve-stimulating expertise). For the Feinstein president, collaboration and discovery set the tone, and the…


Feinstein researchers nab major NIH awards

Two cutting-edge Feinstein Institute for Medical Research projects have been selected for an elite National Institutes of Health funding program. Kevin Tracey, the institute’s president and CEO, and Ping Wang, Feinstein’s chief scientific officer, will continue their groundbreaking research into bioelectronic medicine and sepsis, respectively, with help from the NIH’s Maximizing Investigators’ Research Awards program. Through the NIH’s National Institute of General Medical Sciences – which supports “basic research that increases understanding of biological processes…


Study is big news for Vagus pioneer Tracey

By GREGORY ZELLER // Medical science has taken an enormous step toward “using electronics to replace drugs.” Kevin Tracey’s words sound downright science-fictional. And no, researchers cannot wave a medical tricorder and instantly cure ailments like “Star Trek” medic “Bones” McCoy. But they’re getting closer to a world where high-tech implants – not pharmaceuticals – are the most effective treatments for inflammatory diseases like rheumatoid arthritis and Parkinson’s disease. A recent clinical trial in the…


Feinstein’s Tracey to head bioelectronics summit

Feinstein Institute chief and global bioelectronics pioneer Kevin Tracey will headline a September New York Academy of Science conference on bioelectronic medicine. Tracey, Feinstein’s president and CEO and the brains behind bioelectronic startup Sanguistat, will share keynote duties with Peder Olofsson, a longtime Feinstein Institute researcher and Wallenberg Academy Fellow at the Karolinska Institutet. The two will headline Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms, presented by the Feinstein Institute, the Royal…